

Inactivir® Viral Inactivation Buffer Selection Guide

The Inactivir® range of Viral Inactivation Buffers have been developed to be used in sample tubes to inactivate viral pathogens that are present in patient or other potentially pathogenic samples. The inactivation of viral pathogens on sample collection using Inactivir® will facilitate risk assessments that reduce the requirement for Category 2+/3 handling of potentially pathogenic samples, increasing both the safety of workers and the speed and ease of testing.

A range of Inactivir® buffers are available that have been optimised for specific use cases. This guide will help in the selection of the most appropriate buffer for your use case.

Core Inactivation Buffers

Inactivir® PLUS is a guanidine-based buffer, augmented by REACH-compliant detergent. This is based on published work demonstrating complete viral inactivation of SARS nCoV-19, Ebola, Influenza A & B, RSV and a wide range of other viruses. The UK Government has approved the use of detergent-supplemented guanidine-based buffers for viral inactivation in monkeypox diagnostic testing <https://www.gov.uk/guidance/monkeypox-diagnostic-testing>

This buffer is REACH compliant and features an improved buffer system for stabilisation of RNA in samples.

Inactivir® SD LITE is a non-guanidine buffer that is based on established inactivation principles used in production of human products for several decades with no evidence of viral transmission through those products in the entire timescale. Specific testing has shown inactivation of a wide range of viruses including SARS nCov-19. This buffer is designed for Point of Care (POC) or near-POC testing, with minimal additional components that could interfere with downstream testing. It does not stabilise RNA within samples and is suited for immediate testing use.

Inactivir® SD COMPLETE has the same non-guanidine inactivation system, but additionally contains buffer components that inactivate nucleotide degrading enzymes including RNAses. It therefore stabilizes samples to allow remote testing away from the site of sampling.

Inactivir® SDI includes an additional chaotrope along with the non-guanidine inactivation system. This provides excellent stability for samples and allows the sample to be used directly in silica-based purification systems.

Distributed by:

CliniSciences Group

The following table summarises key properties of **Inactivir®** buffers.

Buffer	Product Code	Guanidine-based	Suitable for 'direct-to-PCR' or 'direct-to-LAMP' assays	Compatible with 'direct to RNA purification'	Stabilize RNA
Inactivir® PLUS	VIB-002	X		X	+++
Inactivir® SD LITE	VIB-003		X		-
Inactivir® SD COMPLETE	VIB-004		X		++
Inactivir® SDI	VIB-005			X	+++

Inactivir® buffers containing chaotrope will denature nucleases and stabilise samples until extracted (+++ for stabilisation). **VIB-004 Inactivir® SD COMPLETE** contains a proprietary stabilisation buffer that provides protection against nuclease degradation but does not fully denature nucleases (++ for stabilisation).

VIB-003 Inactivir® SD LITE does not contain any stabilising agents (- for stabilisation).

All buffers are mucolytic and show rapid reduction in viscosity of saliva and sputum samples when mixed at up to a 1:3 ratio of sample to buffer.

VIB-002 Inactivir® PLUS and **VIB-005 Inactivir® SDI** allow samples to be added directly to silica-based nucleic-acid purifications. These have been validated with both column and magnetic-bead based methods. This means the amount of sample used in the purification can be doubled, as there is no need to add binding buffer in the first step of processing. This will increase sensitivity as twice the amount of sample is purified.

VIB-003 Inactivir® SD LITE and **VIB-004 Inactivir® SD COMPLETE** are capable of being used in some 'direct to PCR' assays. Testing has shown compatibility with standard RT-QPCR reactions for SARS nCoV-19 with addition of 2.5 ul per 20 ul reaction with some manufacturer mastermixes. They have both also been validated for direct-to-LAMP testing methods using published NEB primers and mastermix.

Specialist Application Inactivation Buffers

Inactivir® buffers have been further optimised for specific applications in saliva and 'direct-to' LAMP testing. These mixes are based on the same viral inactivation system as the core buffers, but with changes in the buffers, additives, and concentrations to better suit specific applications.

Distributed by:

CliniSciences Group

Buffer	Product Code:	Stabilise RNA	Enhanced mucolytic buffer	Enhanced buffer for 'direct-to-LAMP' assays	Maximum sample to buffer ratio
Inactivir® SDT	VIB-007	-		X	1:3
Inactivir® SDT COMPLETE	VIB-008	++		X	1:3
Inactivir® SD Saliva	VIB-009	++	X		1:3
Inactivir® SD Saliva 2X	VIB-010	++	X		1:1
Inactivir® SD Saliva 3X	VIB-011	++	X		2:1

VIB-007 Inactivir® SDT and **VIB-008 Inactivir® SDT COMPLETE** are equivalents of VIB-003 Inactivir® SD LITE and VIB-004 Inactivir® SD COMPLETE respectively, but with buffer systems that are optimised for colorimetric 'direct-to-LAMP' assay systems.

VIB-009 Inactivir® SD Saliva, along with **VIB-010 Inactivir® SD Saliva 2X** and **VIB-011 Inactivir® SD Saliva 3X** are inactivation buffers with an enhanced mucolytic system for saliva samples. To optimise the collection of samples the 3 buffers are designed to work at different buffer to sample ratios varying from a **3:1 buffer:sample ratio for VIB-009 Inactivir® SD Saliva**, to a **1:1 ratio for VIB-010 Inactivir® SD Saliva 2X** and a **1:2 ratio for VIB-011 Inactivir® SD Saliva 3X**.

Custom Inactivation Buffers

Life Science Group has an active product development team for Viral Inactivation Buffers, working in collaboration with the University of Bedfordshire. Please contact the company to discuss your inactivation buffer needs or to receive further information concerning any of the above listed products.

Registration

All Inactivir® products are registered as a medical device with MHRA



Distributed by:

CliniSciences Group

CliniSciences Group

Austria

Company: CliniSciences GmbH
Address: Sternwartestrasse 76, A-1180
Wien - Austria
Telephone: +43 720 115 580
Fax: +43 720 115 577
Email: oesterreich@clinisciences.com
Web: <https://www.clinisciences.com>



Belgium

Company: CliniSciences S.R.L
Address: Avenue Stalingrad 52, 1000
Brussels - Belgium
Telephone: +32 2 31 50 800
Fax: +32 2 31 50 801
Email: belgium@clinisciences.com
Web: <https://www.clinisciences.com>



Denmark

Company: CliniSciences ApS
Address: Oesterbrogade 226, st. 1,
Copenhagen, 2100 - Denmark
Telephone: +45 89 888 349
Fax: +45 89 884 064
Email: danmark@clinisciences.com
Web: <https://www.clinisciences.com>



Finland

Company: CliniSciences ApS
Address: Oesterbrogade 226, st. 1,
Copenhagen, 2100 - Denmark
Telephone: +45 89 888 349
Fax: +45 89 884 064
Email: suomi@clinisciences.com
Web: <https://www.clinisciences.com>



France

Company: CliniSciences S.A.S
Address: 74 Rue des Suisses, 92000
Nanterre- France
Telephone: +33 9 77 40 09 09
Fax: +33 9 77 40 10 11
Email: info@clinisciences.com
Web: <https://www.clinisciences.com>



Germany

Company: Biotrend Chemikalien GmbH
Address: Wilhelm-Mauser-Str. 41-43,
50827 Köln - Germany
Telephone: +49 221 9498 320
Fax: +49 221 9498 325
Email: info@biotrend.com
Web: <https://www.biotrend.com>



Iceland

Company: CliniSciences ApS
Address: Oesterbrogade 226, st. 1,
Copenhagen, 2100 - Denmark
Telephone: +45 89 888 349
Fax: +45 89 884 064
Email: island@clinisciences.com
Web: <https://www.clinisciences.com>



Ireland

Company: CliniSciences Limited
Address: Ground Floor, 71 lower Baggot street
Dublin D02 P593 - Ireland
Telephone: +353 1 6971 146
Fax: +353 1 6971 147
Email: ireland@clinisciences.com
Web: <https://www.clinisciences.com>



Italy

Company: CliniSciences S.r.l
Address: Via Maremmana inferiore 378
Roma 00012 Guidonia Montecelio - Italy
Telephone: +39 06 94 80 56 71
Fax: +39 06 94 80 00 21
Email: italia@clinisciences.com
Web: <https://www.clinisciences.com>



Netherlands

Company: CliniSciences B.V.
Address: Kraaijenhoffstraat 137A,
1018RG Amsterdam, Netherlands
Telephone: +31 85 2082 351
Fax: +31 85 2082 353
Email: nederland@clinisciences.com
Web: <https://www.clinisciences.com>



Norway

Company: CliniSciences ApS
Address: Oesterbrogade 226, st. 1,
Copenhagen, 2100 - Denmark
Telephone: +45 89 888 349
Fax: +45 89 884 064
Email: norge@clinisciences.com
Web: <https://www.clinisciences.com>



Poland

Company: CliniSciences sp.Z.o.o.
Address: ul. Rotmistrza Witolda Pileckiego 67
lok. 200 - 02-781 Warszawa -Poland
Telephone: +48 22 307 0535
Fax: +48 22 307 0532
Email: polska@clinisciences.com
Web: <https://www.clinisciences.com>



Portugal

Company: Quimigen Unipessoal LDA
Address: Rua Almada Negreiros, Lote 5, Loja 14,
2615-275 Alverca Do Ribatejo - Portugal
Telephone: +351 30 8808 050
Fax: +351 30 8808 052
Email: info@quimigen.com
Web: <https://www.quimigen.pt>



Spain

Company: CliniSciences Lab Solutions
Address: C/ Hermanos del Moral 13
(Bajo E), 28019, Madrid - Spain
Telephone: +34 91 269 40 65
Fax: +34 91 269 40 74
Email: espana@clinisciences.com
Web: <https://www.clinisciences.com>



Sweden

Company: CliniSciences ApS
Address: Oesterbrogade 226, st. 1,
Copenhagen, 2100 - Denmark
Telephone: +45 89 888 349
Fax: +45 89 884 064
Email: sverige@clinisciences.com
Web: <https://www.clinisciences.com>



Switzerland

Company: CliniSciences Limited
Address: Marktgasse 18 8302 Kloten -
Switzerland
Telephone: +41 (044) 805 76 81
Fax: +41 (044) 805 76 75
Email: switzerland@clinisciences.com
Web: <https://www.clinisciences.com>



UK

Company: CliniSciences Limited
Address: 11 Progress Business center, Whittle
Parkway, SL1 6DQ Slough- United Kingdom
Telephone: +44 (0)1753 866 511
or +44 (0) 330 684 0982
Fax: +44 (0)1753 208 899
Email: uk@clinisciences.com
Web: <https://www.clinisciences.com>



USA

Company: Biotrend Chemicals LLC
Address: c/o Carr Riggs Ingram,
500 Grand Boulevard, Suite 210 Miramar
Beach, FL 32550- USA
Telephone: +1 850 650 7790
Fax: +1 850 650 4383
Email: info@biotrend-usa.com
Web: <https://www.biotrend-usa.com>

